Soligenix Receives EU Orphan Drug Designation for Behçet's Disease Treatment

Soligenix, Inc. (Nasdaq: SNGX) announced that the European Commission has granted Orphan Drug Designation to its drug candidate SGX945 for the treatment of Behçet's Disease. This regulatory milestone follows a positive recommendation from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The decision was primarily supported by clinical data from Phase 2a trials, which demonstrated both biological efficacy and a favorable safety profile. Behçet's Disease is a rare and complex inflammatory disorder, and SGX945 aims to address significant unmet medical needs within this patient population. The designation provides Soligenix with various incentives, including protocol assistance, fee reductions, and potential market exclusivity upon approval. This development marks a critical step forward in the company's clinical development strategy for its late-stage biopharmaceutical pipeline.

Sources:prnewswire.comstreetinsider.comir.soligenix.comnetworknewswire.cominvestorwire.comlongevity.technologygurufocus.comintellectia.ai